GSK to Buy Rapt Therapeutics in Deal Valued at $2.2 Billion
GSK Plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.
By Deirdre Hipwell, Ashleigh Furlong · Bloomberg Markets
GSK Plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.